Related Experiment Video
Updated: May 22, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Management of metastatic castration-resistant prostate cancer: recent advances
Deborah Mukherji1, Andrew Eichholz, Johann S De Bono
1Institute of Cancer Research, Sutton, Surrey, UK.
Abstract:
Metastatic prostate cancer remains a considerable therapeutic challenge; however, advances in clinical research have resulted in five new treatments in the last 2 years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope alpharadin and the anti-androgen MDV3100 have all been shown to improve overall survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. The therapeutic strategies of targeting androgen-receptor signalling and other key intracellular pathways involved in tumour progression and treatment resistance are yielding promising results. Agents such as the dual vascular endothelial growth factor receptor/MET inhibitor cabozantinib, the clusterin inhibitor custirsen and the Src inhibitor dasatinib have shown encouraging results in phase II studies. Novel immunotherapeutics such as prostate-specific membrane antigen-directed therapy and the anti-cytotoxic T lymphocyte-associated receptor 4 (CTLA4) antibody ipilimumab are also under investigation. Optimal methods of treatment selection, combination and sequencing have yet to be determined.
Insights
Recent advances offer new treatments for metastatic prostate cancer, including immunotherapy and targeted therapies. These therapies improve survival for patients with castration-resistant prostate cancer, though optimal treatment strategies are still under investigation.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic prostate cancer presents significant therapeutic challenges.
- Recent clinical research has introduced five novel treatments within the past two years.
Purpose of the Study:
- To review recent advancements in the treatment of metastatic prostate cancer.
- To highlight new therapeutic strategies and agents showing promise in clinical studies.
Main Methods:
- Review of randomized phase III studies for new prostate cancer treatments.
- Analysis of phase II studies for emerging agents.
- Investigation of novel immunotherapeutics.
Main Results:
- Sipuleucel-T, cabazitaxel, abiraterone acetate, alpharadin, and MDV3100 demonstrated improved overall survival in phase III trials for metastatic castration-resistant prostate cancer.
- Targeting androgen-receptor signaling and intracellular pathways shows promise.
- Cabozantinib, custirsen, and dasatinib showed encouraging results in phase II studies.
- Novel immunotherapies, including PSMA-directed therapy and ipilimumab, are under investigation.
Conclusions:
- Several new treatments have emerged for metastatic prostate cancer, improving survival outcomes.
- Targeted therapies and novel immunotherapies represent promising avenues for treatment.
- Further research is needed to determine optimal treatment selection, combination, and sequencing.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers